|View printer-friendly version|
Lorus Therapeutics Reports Third Quarter Results for Fiscal Year 2012
TORONTO, ONTARIO--(April 12, 2012) - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and nine months ended February 29, 2012.
Q3 2012 TO DATE HIGHLIGHTS
"Lorus continues to advance our rich product pipeline." said Dr. Aiping Young, President and CEO of Lorus Therapeutics. "We continue to work diligently to secure the funding we need to continue our ongoing development plan. We believe the combination of funds available under a promissory note, the potential exercise of outstanding warrants and our other financing efforts will provide the funding we need to succeed."
Net loss for the three months ended February 29, 2012 was $1.0 million ($0.05 per share), compared to $1.5 million ($0.10 per share) in the same period in the prior year. The Company incurred a net loss of $3.6 million ($0.18 per share) for the nine months ended February 29, 2012, compared to $3.9 million ($0.32 per share) during the same period in the prior year.
The decrease in net loss in the three and nine month periods ended February 29, 2012 is due to lower general and administrative and research and development expenditures. In the three month period ended February 29, 2012, research and development costs were lower in the current period due to reduced program spending. General and administrative expenses were also lower in the current period due primarily to reduced stock based compensation expense related to option grants in November in the current year compared with December in the prior year. In the nine month period ended February 29, 2012 net loss was reduced due to lower research and development costs in the current year as a result of reduced program spending.
We utilized cash of $740 thousand in our operating activities in the three month period ended February 29, 2012, compared with $1.7 million during the same period in the prior year. For the nine months ended February 29, 2012 we utilized cash of $2.6 million, compared with $4.9 million in the same period last year. The decrease in cash utilized in the three and nine months ended February 29, 2012, compared with the same periods in the prior year, is due to lower cash spending in the current year as well as the advancement of promissory notes in the current year, compared with repayment of outstanding promissory notes in the prior year.
At February 29, 2012, we had cash and cash equivalents of $103 thousand, compared to $911 thousand at May 31, 2011. On November 28, 2011, the Company issued a grid promissory note to Mr. Abramson, a director of Lorus, that allows Lorus to borrow funds of up to $1.8 million. The funds may be borrowed at a rate of up to $300,000 per month, incur interest at a rate of 10% per year and are due and payable on November 28, 2012. At February 29, 2012, $300 thousand had been drawn under the promissory note and subsequent to the quarter end an additional $300 thousand was drawn down for total balance owing of $600 thousand and $1.2 million available for use.
Research and development expenses totaled $543 thousand in the three month period ended February 29, 2012, compared to $847 thousand during the same period in the prior year, and totaled $1.8 million in the nine month period ended February 29, 2012, as compared to $2.0 million in the same period in the prior year. Research and development expenses consisted of the following:
The decrease in research and development costs during the three months ended February 29, 2012, compared with the prior year, is due to decreased stock based compensation expense related to options granted in November in the current year and December in the prior year, as well as lower program costs. After eliminating the effect of the non-cash stock based compensation expense, research and development expenses would be $532 thousand in the three months ended February 29, 2012, compared with $769 thousand in the same period in the prior year, The reduced program expenditures are due primarily to no further spending on our RNA-targeted therapies and subsequent lower personnel and development costs. In the prior year we incurred costs related to the development of a Phase III clinical trial protocol. Spending on our small molecule program is consistent year over year, as the Phase I clinical trial was initiated in January 2011 and is still ongoing.
For the nine month period ended February 29, 2012, research and development spending decreased to $1.8 million, compared with $2.0 million in the same period in the prior year. The decrease is attributable to a reduction in program spending to $1.6 million, compared with $1.9 million in the same period in the prior year. The decrease from the prior year is due to no further spending on our RNA-targeted therapies, compared with $508 thousand in the prior year. This reduction is offset by higher resources allocated to the development of our small molecule programs, in particular the ongoing Phase I clinical trial for LOR-253, and the LOR-500 discovery program.
General and administrative expenses totaled $479 thousand in the three-month period ended February 29, 2012, compared to $701 thousand in same period in the prior year. For the nine month period ended February 29, 2012, general and administrative expenses were $1.8 million, compared with $1.9 million in the same period in the prior year.
Components of general and administrative expenses:
Stock based compensation expense was lower in the three month periods ended February 29, 2012, compared with the same period in the prior year, due to options issued in November in the current year. compared with December in the prior year. As a result of immediate vesting of certain options, the expense tends to be higher in the quarter the options are issued, compared with subsequent quarters. Stock based compensation expense was higher in the nine month periods ended February 29, 2012, compared with the same period in the prior year, due to certain one time grants in the current year and the cancellation of certain outstanding options (resulting in the acceleration of expense), which increased stock based compensation charges.
General and administrative expenses, excluding salaries, were consistent in the three months ended February 29, 2012, compared with the same period in the prior year. In the nine months ended February 29, 2012, general and administrative expenses, excluding salaries, were lower than the prior year, due to financing fees incurred in the prior year related to a terminated financing. This was partially offset by higher audit related fees due to additional review work and the transition to IFRS in the current year. In the three and nine month periods ended February 29, 2012, salary costs compared with the prior year were lower due to a reduction in headcount in the current year.
Management has forecasted that the Corporation's current level of cash, cash equivalents and short-term investments is not sufficient to execute its current planned expenditures for the next twelve months without further investment. The Corporation is currently in discussion with several potential investors to provide additional funding. The Corporation also continues to pursue partnership opportunities. Management believes that it will complete one or more of these arrangements in sufficient time to continue to execute its planned expenditures without interruption. However, there can be no assurance that the capital will be available as necessary to meet these continuing expenditures, or if the capital is available, that it will be on terms acceptable to the Corporation.
As of April 12, 2012, a total of $600,000 has been drawn on the grid promissory note issued to Mr. Abramson, leaving $1.2 million available for future use.
Lorus is a biopharmaceutical company focused on the discovery, research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: the ability of the company to continue as a going concern, the ability to find and secure future financing, the probability that warrants maybe exercised, that funds will continue to be available under the promissory note, the establishment of corporate alliances or partnerships, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward-looking statements could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.